Log in

NASDAQ:HOOK - Hookipa Pharma Stock Price, Forecast & News

$12.30
+0.26 (+2.16 %)
(As of 02/19/2020 08:00 AM ET)
Today's Range
$12.05
Now: $12.30
$12.64
50-Day Range
$11.13
MA: $12.08
$13.80
52-Week Range
$6.06
Now: $12.30
$14.76
Volume51,700 shs
Average Volume89,539 shs
Market Capitalization$265.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HOOK
CUSIPN/A
CIKN/A
Phone431-890-6360

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees56
Market Cap$265.56 million
Next Earnings DateN/A
OptionableNot Optionable

Receive HOOK News and Ratings via Email

Sign-up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.


Hookipa Pharma (NASDAQ:HOOK) Frequently Asked Questions

What is Hookipa Pharma's stock symbol?

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) issued its earnings results on Tuesday, November, 12th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.21. The firm earned $2.04 million during the quarter, compared to analyst estimates of $2.35 million. View Hookipa Pharma's Earnings History.

What price target have analysts set for HOOK?

5 analysts have issued 1-year price targets for Hookipa Pharma's stock. Their forecasts range from $15.00 to $23.00. On average, they anticipate Hookipa Pharma's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 54.5% from the stock's current price. View Analyst Price Targets for Hookipa Pharma.

What is the consensus analysts' recommendation for Hookipa Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hookipa Pharma.

Has Hookipa Pharma been receiving favorable news coverage?

News articles about HOOK stock have been trending negative on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Hookipa Pharma earned a daily sentiment score of -2.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Hookipa Pharma.

Are investors shorting Hookipa Pharma?

Hookipa Pharma saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 196,700 shares, a drop of 33.9% from the January 15th total of 297,700 shares. Based on an average daily volume of 105,200 shares, the days-to-cover ratio is currently 1.9 days. Approximately 1.7% of the shares of the stock are short sold. View Hookipa Pharma's Current Options Chain.

Who are some of Hookipa Pharma's key competitors?

What other stocks do shareholders of Hookipa Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Pfizer (PFE), Exxon Mobil (XOM), Alector (ALEC), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Verizon Communications (VZ), Akero Therapeutics (AKRO) and Axsome Therapeutics (AXSM).

Who are Hookipa Pharma's key executives?

Hookipa Pharma's management team includes the folowing people:
  • Mr. Joern Aldag, Pres, CEO & Director (Age 60)
  • Mr. Daniel Pinschewer, Founder & Chief Scientific Officer (Age 44)
  • Dr. Reinhard Kandera, CFO & Director (Age 50)
  • Mr. Anders Lilja Ph.D., Sr. VP of Technical Devel. (Age 46)
  • Mrs. Nina Waibel, Communications & Investor Relations Mang.

When did Hookipa Pharma IPO?

(HOOK) raised $100 million in an initial public offering (IPO) on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

Who are Hookipa Pharma's major shareholders?

Hookipa Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (2.27%), State Street Corp (0.43%), Bank of New York Mellon Corp (0.13%), Charles Schwab Investment Management Inc. (0.10%), UBS Group AG (0.06%) and Bank of America Corp DE (0.05%). Company insiders that own Hookipa Pharma stock include Anders Lilja, Bros Advisors Lp Baker, Igor Matushansky, Klaus Orlinger and Sofinnova Capital Vi Fcpr. View Institutional Ownership Trends for Hookipa Pharma.

Which institutional investors are selling Hookipa Pharma stock?

HOOK stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Bank of America Corp DE. Company insiders that have sold Hookipa Pharma company stock in the last year include Anders Lilja, Igor Matushansky and Klaus Orlinger. View Insider Buying and Selling for Hookipa Pharma.

Which institutional investors are buying Hookipa Pharma stock?

HOOK stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, UBS Group AG, Barclays PLC and American International Group Inc.. Company insiders that have bought Hookipa Pharma stock in the last two years include Bros Advisors Lp Baker and Sofinnova Capital Vi Fcpr. View Insider Buying and Selling for Hookipa Pharma.

How do I buy shares of Hookipa Pharma?

Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hookipa Pharma's stock price today?

One share of HOOK stock can currently be purchased for approximately $12.30.

How big of a company is Hookipa Pharma?

Hookipa Pharma has a market capitalization of $265.56 million. Hookipa Pharma employs 56 workers across the globe.View Additional Information About Hookipa Pharma.

What is Hookipa Pharma's official website?

The official website for Hookipa Pharma is http://www.hookipapharma.com/.

How can I contact Hookipa Pharma?

Hookipa Pharma's mailing address is 350 Fifth Avenue 72nd Floor Suite 7240, New York NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected]


MarketBeat Community Rating for Hookipa Pharma (NASDAQ HOOK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  36 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Hookipa Pharma and other stocks. Vote "Outperform" if you believe HOOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel